Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Basic Research in Cardiology

• Publication date

  2000-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s003950070041PMID 11099169
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability.

  1999cited by this paper
• Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease.

  1999cited by this paper
• Epidemiological classification of acute myocardial infarction: time for a change?

  1999cited by this paper
• C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.

  1999cited by this paper
• Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke.

  1998cited by this paper
• Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries.

  1998cited by this paper
• C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy

  1998cited by this paper
• Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease.

  1998cited by this paper
• Nonatherosclerotic Regions of Human Arteries in Atherosclerotic and 2 Ultrastructural Localization of Secretory Type II Phospholipase A

  1998cited by this paper
• C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men

  1998cited by this paper
• Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

  1997cited by this paper
• Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall.

  1997cited by this paper
• Phospholipase-A2-dependent signalling in the heart

  1995cited by this paper
• Phospholipase-A2-dependent signalling in the heart.

  1995cited by this paper
• Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture

  1994cited by this paper
• Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology.

  1994cited by this paper
• The pathogenesis of atherosclerosis: a perspective for the 1990s

  1993cited by this paper
• The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

  1992cited by this paper
• Immunochemical detection of group I and group II phospholipases A2 in human serum.

  1992cited by this paper

• Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval

  2018cites this paper
• Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease

  2015cites this paper
• Phospholipase A2 enzymes and the risk of atherosclerosis.

  2012cites this paper
• Activated platelets contribute to oxidized low‐density lipoproteins and dysfunctional high‐density lipoproteins through a phospholipase A2‐dependent mechanism

  2012cites this paper
• Novel therapeutic concepts Phospholipase A 2 enzymes and the risk of atherosclerosis

  2012cites this paper
• Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.

  2011cites this paper
• Anti-Inflammatory Effects of Varespladib Methyl in Diabetic Patients with Acute Coronary Syndrome

  2011cites this paper
• Degeneration and atherosclerosis inducing increased deposition of type IIA secretory phospholipase A2, C-reactive protein and complement in aortic valves cause neutrophilic granulocyte influx.

  2011cites this paper
• Secretory phospholipase A2 in patients with coronary artery disease

  2010cites this paper
• Varespladib methyl in cardiovascular disease

  2010cites this paper
• MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction

  2010cites this paper
• Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes

  2010cites this paper
• Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.

  2010cites this paper
• Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease

  2009cites this paper
• A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs

  2009cites this paper
• Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial.

  2009cites this paper
• The role of inflammation in the pathophysiology of acute myocardial infarction

  2009cites this paper
• Potential Relevance of α1-Adrenergic Receptor Autoantibodies in Refractory Hypertension

  2008cites this paper
• Secretory type II phospholipase A2 in culprit coronary lesions is associated with myocardial infarction

  2008cites this paper
• Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis.

  2006cites this paper
• Thematic review series : The Immune System and Atherogenesis Lipoprotein-associated inflammatory proteins : markers or mediators of cardiovascular disease ?

  2005cites this paper
• Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? Published, JLR Papers in Press, February 1, 2005. DOI 10.1194/jlr.R400017-JLR200

  2005cites this paper
• Advances in routine measurement of cardiac damage and cardiovascular risk markers

  2005cites this paper
• Fusion and atherogenic properties of enzymatically modified low density lipoprotein particles

  2005cites this paper
• Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes.

  2003cites this paper
• Phospholipase A2 in the pathogenesis of cardiovascular disease

  2003cites this paper
• [Serum level of secretory phospholipase A2 (sPLA2) as a predictor of restenosis after coronary angioplasty].

  2002cites this paper
• Antioxidant vitamins and lipid peroxidation in patients with rheumatoid arthritis: association with inflammatory markers.

  2002cites this paper
• Phospholipase A(2) in vascular disease.

  2001cites this paper